Tags

Type your tag names separated by a space and hit enter

Specific microbicides in the prevention of HIV infection.
J Intern Med. 2011 Dec; 270(6):509-19.JI

Abstract

Microbicides are products that are designed for application at vaginal or rectal mucosae to inhibit or block early events in HIV infection and thereby prevent transmission of HIV. Currently, the most advanced microbicides in the development pipeline are based on highly active anti-retroviral drugs (ARVs). Significant protection of women by vaginally applied tenofovir gel, demonstrated in the CAPRISA 004 trial, has provided proof-of-concept that microbicides can be effective. The rationale for investigating ARVs and other compounds as vaginal or rectal microbicides is discussed together with approaches to improve efficacy by the development of combination microbicides and by new formulations that may increase user acceptance.

Authors+Show Affiliations

King's College London, Dental Institute, London, UK. charles.kelly@kcl.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21917029

Citation

Kelly, C G., and R J. Shattock. "Specific Microbicides in the Prevention of HIV Infection." Journal of Internal Medicine, vol. 270, no. 6, 2011, pp. 509-19.
Kelly CG, Shattock RJ. Specific microbicides in the prevention of HIV infection. J Intern Med. 2011;270(6):509-19.
Kelly, C. G., & Shattock, R. J. (2011). Specific microbicides in the prevention of HIV infection. Journal of Internal Medicine, 270(6), 509-19. https://doi.org/10.1111/j.1365-2796.2011.02454.x
Kelly CG, Shattock RJ. Specific Microbicides in the Prevention of HIV Infection. J Intern Med. 2011;270(6):509-19. PubMed PMID: 21917029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific microbicides in the prevention of HIV infection. AU - Kelly,C G, AU - Shattock,R J, Y1 - 2011/10/27/ PY - 2011/9/16/entrez PY - 2011/9/16/pubmed PY - 2012/1/13/medline SP - 509 EP - 19 JF - Journal of internal medicine JO - J Intern Med VL - 270 IS - 6 N2 - Microbicides are products that are designed for application at vaginal or rectal mucosae to inhibit or block early events in HIV infection and thereby prevent transmission of HIV. Currently, the most advanced microbicides in the development pipeline are based on highly active anti-retroviral drugs (ARVs). Significant protection of women by vaginally applied tenofovir gel, demonstrated in the CAPRISA 004 trial, has provided proof-of-concept that microbicides can be effective. The rationale for investigating ARVs and other compounds as vaginal or rectal microbicides is discussed together with approaches to improve efficacy by the development of combination microbicides and by new formulations that may increase user acceptance. SN - 1365-2796 UR - https://www.unboundmedicine.com/medline/citation/21917029/Specific_microbicides_in_the_prevention_of_HIV_infection_ L2 - https://doi.org/10.1111/j.1365-2796.2011.02454.x DB - PRIME DP - Unbound Medicine ER -